Nama's AI scorecard currently rates NewAmsterdam Pharma Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does NAMS report earnings?

NewAmsterdam Pharma's next scheduled report is on Feb 17, 2027. Analysts expect EPS of -$0.40.

What is the NAMS price target?

The median analyst price target from 14 analysts is $50.53, with a range of $37.83 – $59.00.

Is NAMS Shariah compliant?

Nama's AAOIFI-style screen reads NewAmsterdam Pharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

NewAmsterdam Pharma (NAMS)

Healthcare · Biotechnology · NASDAQ

NewAmsterdam Pharma (NAMS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.27B and a free-cash-flow yield of -6.8%. Over the most recent reported fiscal year, revenue declined 50.6%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 2.5/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Trailing · -40.3% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-55.2%

How far the last close sits under the highest price of the past five years.

Market cap	$2.27B
Trailing P/E	—
Price / book	3.5
Price / sales	315.0
FCF yield	-6.8%
Dividend yield	—
Gross margin	100.0%
Operating margin	-1752.6%
Net margin	0.0%
Revenue growth (YoY)	-50.6%
Revenue growth (3-yr annual)	-39.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

NAMS earnings

Next report: Feb 17, 2027 (Q4 2026, EPS estimate -$0.40). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.12	-$0.44	+72.7%	$19.16M
Q2 2026	Aug 5, 2026	-$0.45	-$0.43	-4.7%	$3.70M
Q1 2026	May 7, 2026	-$0.34	-$0.41	+17.1%	$3.04M
Q4 2025	Feb 18, 2026	-$0.53	-$0.37	-43.2%	$32,000

NAMS analyst price target

Median target $50.53 from 14 analysts, ranging $37.83 – $59.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live NAMS data on Nama Insights →

NAMS FAQ

Is NAMS a buy?: Nama's AI scorecard currently rates NewAmsterdam Pharma Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NAMS report earnings?: NewAmsterdam Pharma's next scheduled report is on Feb 17, 2027. Analysts expect EPS of -$0.40.
What is the NAMS price target?: The median analyst price target from 14 analysts is $50.53, with a range of $37.83 – $59.00.
Is NAMS Shariah compliant?: Nama's AAOIFI-style screen reads NewAmsterdam Pharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.